Prandin
$ 40,00 – $ 858,00Price range: $ 40,00 through $ 858,00
Pravachol
$ 67,00 – $ 395,00Price range: $ 67,00 through $ 395,00
Prasugrel
$ 54,00 – $ 462,00Price range: $ 54,00 through $ 462,00
Prasugrel is a highly effective antiplatelet agent used to prevent the formation of harmful blood clots in the cardiovascular system. It is specifically indicated for patients with acute coronary syndrome who are undergoing a procedure to open narrowed or blocked arteries. The medication works by keeping platelets in the blood from clumping together, thereby reducing the chance of experiencing a subsequent heart attack. This treatment is vital for maintaining the openness of coronary stents and improving blood circulation following significant cardiac events. Consistent use of Prasugrel provides essential protection against life-threatening thrombotic complications in high-risk cardiovascular patients.
Active substance: Prasugrel
SKU:
Prasugrel
Category: Heart Disease
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM
Each dosage option has its own packaging choices.
Description
Prasugrel belongs to a class of medications known as thienopyridine P2Y12 platelet inhibitors. It is prescribed under federal law as a prescription-only (Rx) treatment to reduce the risk of dangerous blood clots in individuals undergoing specific cardiac interventions. When evaluating its role in cardiovascular care, healthcare providers balance its potent antiplatelet effects against the inherent risk of bleeding complications.
This medication is primarily indicated for patients diagnosed with acute coronary syndrome who are managed with percutaneous coronary intervention, such as angioplasty or stent placement. Understanding how prasugrel operates in the body, adhering to prescribed dosing protocols, and recognizing important safety warnings are essential steps in managing treatment effectively under medical supervision.
Key Information Overview
| Parameter | Details |
|---|---|
| Drug Name | Prasugrel |
| Active Ingredient | Prasugrel hydrochloride |
| Pharmacologic Class | P2Y12 platelet inhibitor (Thienopyridine) |
| Route of Administration | Oral |
| Prescription Status | Prescription (Rx) only |
| Primary Purpose | Reduction of thrombotic cardiovascular events |
Clinical Overview and Pharmacological Profile
Main uses
Prasugrel is indicated to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention (PCI). This clinical category includes individuals presenting with unstable angina, non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI). While the medication provides robust protection against blood clot formation inside newly placed coronary stents, its approved indication is strictly limited to patients undergoing PCI. Conversely, prasugrel is not recommended for patients with acute coronary syndrome who are managed solely with medical therapy without invasive intervention, as clinical trials have not demonstrated a favorable risk-benefit balance in that specific population.
How the drug works
As an oral prodrug, prasugrel requires metabolic conversion in the body to generate its active biological form. Once activated, it irreversibly binds to the P2Y12 class of adenosine diphosphate (ADP) receptors on blood platelets. By permanently blocking these receptors, the drug prevents ADP-mediated activation of the glycoprotein IIb/IIIa complex, thereby inhibiting platelet activation and aggregation for the remainder of the platelet’s natural life cycle. On one hand, this irreversible binding provides consistent, rapid, and potent antiplatelet protection to prevent vessel re-occlusion following cardiac procedures. On the other hand, because platelet function is persistently reduced, the body’s standard blood-clotting mechanisms are delayed, elevating the likelihood of bleeding.
What happens in the body
Following oral administration, prasugrel is rapidly absorbed in the gastrointestinal tract and rapidly hydrolyzed by intestinal carboxylesterases into an intermediate metabolite. This intermediate undergoes subsequent conversion into the active metabolite primarily by cytochrome P450 enzymes CYP3A4 and CYP2C19. Peak plasma concentrations of the active metabolite are typically achieved within approximately 30 minutes after ingestion. The active metabolite itself has an elimination half-life of roughly 7.4 hours; however, its pharmacological effect persists for the lifetime of circulating platelets, which is approximately 7 to 10 days. Elimination occurs primarily through renal excretion, with roughly 68% of the metabolite recovered in urine and 27% excreted in feces.
Dosing schedule
Treatment with prasugrel is initiated with a single 60 mg oral loading dose, typically administered upon presentation or during the PCI procedure. Following the loading dose, the standard maintenance regimen is 10 mg taken orally once daily. Guidelines also direct patients to take a daily low-dose aspirin (75 mg to 325 mg) concurrently with prasugrel, unless explicitly contraindicated. For patients weighing less than 60 kg (132 lbs), a reduced daily maintenance dose of 5 mg is generally considered due to an observed increase in active metabolite exposure and bleeding risk in lower-weight individuals. Tablets may be taken with or without food, but should be taken at the same time each day without crushing or splitting.
Safety Guidelines and Daily Management
Important precautions
Prasugrel carries significant safety considerations that require careful clinical evaluation before starting therapy. The medication carries a prominent black box warning regarding potentially severe or fatal bleeding risks. It is strictly contraindicated in patients with active pathological bleeding, such as peptic ulcers or intracranial hemorrhages, as well as individuals with a history of transient ischemic attack (TIA) or stroke. Furthermore, prasugrel is generally not recommended in patients aged 75 years or older due to an elevated risk of fatal and intracranial bleeding, except in high-risk clinical scenarios where the therapeutic benefit is deemed to outweigh the risks by the prescribing physician. Pregnant or nursing individuals should discuss treatment carefully, as safety data in these populations remain limited.
Adverse reactions
The primary adverse effect linked to prasugrel is bleeding, which ranges in severity from minor to life-threatening. Common, minor bleeding events include persistent nosebleeds, easy bruising, small hematomas, bleeding gums during oral hygiene, and prolonged bleeding from minor cuts. While these mild occurrences are expected consequences of antiplatelet therapy, severe adverse reactions can occur. These include major gastrointestinal bleeding, retroperitoneal hemorrhage, and significant drops in hemoglobin or red blood cell counts. Additionally, a rare but life-threatening condition called Thrombotic Thrombocytopenic Purpura (TTP) has been reported with thienopyridine administration, requiring immediate emergency medical evaluation if suspected.
Compatibility with other medicines
Combining prasugrel with other medications that modify blood coagulation significantly increases the risk of bleeding. Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, or high-dose aspirin, requires strict medical supervision. Similarly, oral anticoagulants, including warfarin, dabigatran, rivaroxaban, or apixaban, should generally not be combined with prasugrel unless specifically instructed by a cardiologist. Fibrinolytic agents and chronic systemic corticosteroids also heighten hemorrhagic risks. Conversely, unlike some other antiplatelet drugs, the metabolic activation of prasugrel is not significantly impaired by common acid-reducing medications like proton pump inhibitors (e.g., omeprazole), allowing co-administration when clinically indicated.
First days of treatment
During the initial days of taking prasugrel, patients often notice physical signs related to reduced blood clotting. Minor bumps may result in larger or darker bruises than usual, and small abrasions or razor nicks may require longer pressure to stop bleeding. These observations reflect the expected activity of the medication. It is advisable to adopt minor precautions early on, such as using an electric razor, opting for a soft-bristled toothbrush, and taking extra care when handling sharp objects. Understanding these early changes helps distinguish between normal antiplatelet effects and signs of excessive bleeding.
Signs of improvement
Unlike medications designed to lower blood pressure or treat pain, prasugrel does not produce obvious physical sensations that signal it is working. Instead, its primary therapeutic effect is preventative–keeping blood vessels and newly implanted coronary stents clear of dangerous blood clots. Laboratory testing, such as specific platelet aggregation assays, can evaluate the extent of platelet inhibition if required by a physician. The true indicator of successful treatment is the ongoing prevention of recurrent cardiac ischemic events, stent thrombosis, or secondary heart attacks throughout the course of therapy.
If you skip a dose
If a dose of prasugrel is missed, it should be taken as soon as it is remembered on the same day. However, if it is almost time for the next scheduled dose, the missed pill should be skipped entirely, and the normal dosing schedule should be resumed. Patients should never double the dose or take extra tablets to make up for a missed day. Taking extra medication significantly heightens the danger of acute bleeding. Using a daily pill planner or setting a phone reminder can help maintain consistency and lower the risk of missing doses.
Storage and expiration
Prasugrel tablets should be stored at controlled room temperature, between 68°F and 77°F (20°C to 25°C), with permitted excursions between 59°F and 86°F (15°C to 30°C). The medication must be kept in its original container to protect the tablets from atmospheric moisture and environmental degradation. The bottle should remain tightly sealed and kept away from areas with high humidity, such as bathroom cabinets. Always check the expiration date stamped on the package and dispose of any expired or unused medication through official community pharmacy disposal programs in compliance with federal guidelines.
Emergency Warning Signs
| Symptom / Red Flag | Action Required |
|---|---|
| Bleeding from cuts or nosebleeds that will not stop after applying pressure | Seek emergency medical care immediately |
| Black, tarry, or bloody stools | Seek emergency medical care immediately |
| Pink, red, or dark brown urine | Seek emergency medical care immediately |
| Coughing up blood or vomiting material that looks like coffee grounds | Seek emergency medical care immediately |
| Sudden weakness, numbness, difficulty speaking, or vision changes | Seek emergency medical care immediately |
| Unusual, severe headache or sudden dizziness | Seek emergency medical care immediately |
Frequently Asked Questions
Q: Can I stop taking prasugrel before a scheduled surgery or dental procedure?
A: You should never stop taking prasugrel without direct instruction from your cardiologist. Premature discontinuation significantly increases the risk of stent thrombosis and heart attack. When elective surgery or dental procedures requiring bleeding control are necessary, physicians typically recommend temporarily discontinuing prasugrel at least 7 days prior to the procedure, but only after weighing the risk of cardiovascular events against the risk of surgical bleeding.
Q: Why is prasugrel generally avoided in patients with a history of stroke or TIA?
A: Clinical trials demonstrated that patients with a prior history of stroke or transient ischemic attack (TIA) experienced a significantly higher risk of severe intracranial bleeding when treated with prasugrel, without a net clinical benefit. Because the risk of brain hemorrhage in this population outweighs the protective cardiovascular effects, FDA labeling strictly contraindicates prasugrel in anyone with a history of TIA or stroke.
Q: What should I do if I notice unusual bruising or minor nosebleeds?
A: Minor bruising and occasional brief nosebleeds are common side effects of antiplatelet therapy. You should document these occurrences and inform your prescribing doctor during regular follow-ups. However, if a nosebleed persists for more than 15 to 20 minutes despite applying firm pressure, or if bruises are unusually large, painful, or expanding rapidly, seek medical attention promptly.
Q: Does taking prasugrel with food affect how well it works?
A: Prasugrel can be taken with or without food. High-fat meals may slightly delay the time it takes for the active metabolite to reach peak concentration in the bloodstream, but this delay does not significantly impact the overall extent of platelet inhibition or clinical effectiveness during maintenance therapy. Taking the tablet with meals may help if you experience mild stomach upset.
Q: Can I take over-the-counter pain relievers like ibuprofen while on prasugrel?
A: Combining nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen with prasugrel increases the risk of gastrointestinal ulcers and bleeding. You should avoid taking over-the-counter NSAIDs unless your healthcare provider explicitly approves them. Acetaminophen is often recommended as an alternative for mild pain management, but always consult your pharmacist or doctor before taking any new medication.
Information on this page is for reference and does not replace an assessment by a licensed healthcare professional. In accordance with FDA requirements.
Additional information
| Dosage |
5 mg ,10 mg |
|---|---|
| Package |
30 pills ,60 pills ,90 pills ,120 pills ,180 pills ,360 pills |
| Ενεργός Ουσία |
Related products
Abana
$ 89,00 – $ 580,00Price range: $ 89,00 through $ 580,00
Active substance: Abana
More Details
This product has multiple variants. The options may be chosen on the product page
Aldactone
$ 33,00 – $ 345,00Price range: $ 33,00 through $ 345,00
Active substance: Spironolactone
More Details
This product has multiple variants. The options may be chosen on the product page
Bystolic
$ 38,00 – $ 275,00Price range: $ 38,00 through $ 275,00
Active substance: Nebivolol
More Details
This product has multiple variants. The options may be chosen on the product page
Calan
$ 46,00 – $ 242,00Price range: $ 46,00 through $ 242,00
Active substance: Verapamil
More Details
This product has multiple variants. The options may be chosen on the product page
Coreg
$ 41,00 – $ 651,00Price range: $ 41,00 through $ 651,00
Active substance: Carvedilol
More Details
This product has multiple variants. The options may be chosen on the product page
Coversyl
$ 40,00 – $ 540,00Price range: $ 40,00 through $ 540,00
Active substance: perindopril arginine
More Details
This product has multiple variants. The options may be chosen on the product page
Ecosprin
$ 19,00 – $ 57,00Price range: $ 19,00 through $ 57,00
Active substance: aspirin
More Details
This product has multiple variants. The options may be chosen on the product page
Isordil
$ 51,00 – $ 151,00Price range: $ 51,00 through $ 151,00
Active substance: isosorbide dinitrate
More Details
This product has multiple variants. The options may be chosen on the product page
